Research programme: enzyme replacement therapy - Zymenex

Drug Profile

Research programme: enzyme replacement therapy - Zymenex

Alternative Names: Agazym; Aspartylglucosaminuria; Galaczym; Recombinant lysosomal galactocerebrosidase; rhAGA; rhGALC; ZA 011

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Zymenex A/S
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Amidohydrolase replacements; Galactosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Globoid cell leukodystrophy; Lysosomal storage diseases
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Globoid cell leukodystrophy
  • Research Lysosomal storage diseases

Most Recent Events

  • 04 Oct 2016 Preclinical development is ongoing for Globoid cell leukodystrophy in Denmark (Zymenex pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Globoid-cell-leukodystrophy in Denmark
  • 08 Oct 2015 Early research in Lysosomal storage diseases in Denmark (unspecified route) before October 2015 (Zymenex pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top